Literature DB >> 27510010

Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT.

Chanisa Chotipanich1, Anchisa Kunawudhi, Chetsadaporn Promteangtrong, Puntira Tungsuppawattanakit, Thaniya Sricharunrat, Paramest Wongsa.   

Abstract

PURPOSE: The aim of this study was to compare C11 choline and F18 FDG PET/CT, gadoxeticenhanced 3T MRI and contrastenhanced CT for diagnosis of hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Twelve chronic hepatitis B patients suspected of having HCC by abdominal ultrasonography received all diagnostic modalities performed within a oneweek timeslot. PET/CT results were analyzed visually by two independent nuclear medicine physicians and quantitatively by tumor to background ratio (T/B). Nine patients then had histopathological confirmation.
RESULTS: Six patients had well differentiated HCC, while two and one patient(s) were noted with moderately and poorly differentiated HCC, respectively. All were detected by both CT and MRI with an average tumor size of 5.7±3.8 cm. Five patients had positive C11 choline and F18 FDG uptake. Of the remaining four patients, three with well differentiated HCC showed negative FFDG uptake (one of which showed negative results by both tracers) and one patient with moderately differentiated HCC demonstrated no C11 choline uptake despite intense F18 FDG avidity. The overall HCC detection rates with C11 choline and F18 FDG were 78% and 67%, respectively, while the sensitivity of F18 FDG for nonwell differentiated HCC was 100%, compared with 83% of C11 choline. The average T/B of C11 choline in welldifferentiated HCC patients was higher than in moderately and poorly differentiated cases (p=0.5) and vice versa with statistical significance for T/B of F18 FDG (p = 0.02).
CONCLUSIONS: Our results suggested better detection rate in C11 choline for well differentiated HCC than F18 FDG PET. However, the overall detection rate of PET/CT with both tracers could not compare with contrastenhanced CT and MRI.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27510010

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-10       Impact factor: 2.485

2.  Validation of R-2-[18F]Fluoropropionic Acid as a Potential Tracer for PET Imaging of Liver Cancer.

Authors:  Zhanwen Zhang; Shaoyu Liu; Hui Ma; Dahong Nie; Fuhua Wen; Jing Zhao; Aixia Sun; Gongjun Yuan; Shu Su; Xianhong Xiang; Ping Hu; Ganghua Tang
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

3.  Sodium Pump Na + /K + ATPase Subunit α1-Targeted Positron Emission Tomography Imaging of Hepatocellular Carcinoma in Mouse Models.

Authors:  Si Tang; XiaoChun Yang; Chao Zhou; Yan Mei; JiaCong Ye; XiaoFei Zhang; GuoKai Feng; WeiGuang Zhang; Xu Zhang; Wei Fan
Journal:  Mol Imaging Biol       Date:  2021-10-07       Impact factor: 3.488

4.  PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617.

Authors:  Qiaomiao Lu; Yu Long; Kevin Fan; Zhiwen Shen; Yongkang Gai; Qingyao Liu; Dawei Jiang; Weibo Cai; Chidan Wan; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-28       Impact factor: 10.057

Review 5.  18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches.

Authors:  Arno Kornberg; Helmut Friess
Journal:  Therap Adv Gastroenterol       Date:  2019-03-19       Impact factor: 4.802

Review 6.  18F-FDG /18F-Choline Dual-Tracer PET Behavior and Tumor Differentiation in HepatoCellular Carcinoma. A Systematic Review.

Authors:  Jérôme Ghidaglia; Nicolas Golse; Alina Pascale; Mylène Sebagh; Florent L Besson
Journal:  Front Med (Lausanne)       Date:  2022-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.